Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of itepekimab in adults with chronic rhinosinusitis with nasal polyps
NL-OMON61123Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jun 2026; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON61123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61123.